Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates

Southern Medical Journal

Volumn 102, Issue 5, 2009, Pages 486-492

  Binkley, Neil ^a   Martens, Mark G ^b   Silverman, Stuart L ^b   Derman, Richard J ^b   Greenwald, Maria ^b   Kohles, Joseph D ^b   Bachmann, Gloria A ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

Bisphosphonates; Gastrointestinal intolerance; Ibandronate; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; IBANDRONIC ACID; RISEDRONIC ACID; VITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OSTEOPENIA; OSTEOPOROSIS PATIENT SATISFACTION QUESTIONNAIRE; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; QUESTIONNAIRE; SCREENING; STOMACH DISCOMFORT; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT SATISFACTION;

EID: 65649132234     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31819ed0dd     Document Type: Article

References (28)

1. Chesnut CH III, Skag A, Christiansen C, et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
2. Black DM, Thompson DE. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract Suppl 1999;101:46-50.
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
4. Rizzoli R. Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res 2006;443:61-65.
5. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 2000;1:225-238.
6. Hamilton B, McCoy K, Taggart HT. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-262. (Pubitemid 40826240)
7. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119:631-638. (Pubitemid 30681121)
8. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021.
9. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377-1382. (Pubitemid 28506801)
10. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
11. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-468. (Pubitemid 29231740)
12. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
13. Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391-401. (Pubitemid 40490679)
14. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevelance of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm 1998;4:488-492.
15. Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236-242. (Pubitemid 44287822)
16. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022.
17. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031-1043.
18. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007;30:755-763. (Pubitemid 47351214)
19. Lanza FL. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat Endocrinol 2002;1:37-43.
20. Koltun W, Emkey RD, Kroll R, et al. Monthly ibandronate is more tolerable than weekly alendronate - results of BALTO I and II studies. Obstet Gynecol 2007;109:98S. [abstract]
21. Bonnick SL, Silverman SL, Tanner SB, et al. Patient satisfaction in postmenopausal women treated with a weekly biophosphonate transitioned to once-monthly ibandronate. J Womens Health 2009. In press.
22. Flood EM, Beusterien KM, Green H, et al. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes. 2006;4:42. Available at: http://www.hqlo.com/ content/4/1/42/additional/. Accessed May 14, 2008. (Pubitemid 44241604)
23. Rossini M, Bianchi G, Di Munno O, et al; Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-921.
24. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-216.
25. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008.
26. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-968.
27. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000;22:1433-1442. (Pubitemid 32056082)
28. Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf 2002;1:71-78.